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ABSTRACT
Introduction Antiepileptic drugs (AEDs) are the mainstay 
of epilepsy treatment. Over the past 20 years, a number of 
new drugs have been approved for National Health Service 
(NHS) use on the basis of information from short- term 
trials that demonstrate efficacy. These trials do not provide 
information about the longer term outcomes, which inform 
treatment policy. This trial will assess the long- term 
clinical and cost- effectiveness of the newer treatment 
levetiracetam and zonisamide.
Methods and analysis This is a phase IV, multicentre, 
open- label, randomised, controlled clinical trial comparing 
new and standard treatments for patients with newly 
diagnosed epilepsy. Arm A of the trial randomised 990 
patients with focal epilepsy to standard AED lamotrigine or 
new AED levetiracetam or zonisamide. Arm B randomised 
520 patients with generalised epilepsy to standard AED 
sodium valproate or new AED levetiracetam. Patients 
are recruited from UK NHS outpatient epilepsy, general 
neurology and paediatric clinics. Included patients are 
aged 5 years or older with two or more spontaneous 
seizures requiring AED monotherapy, who are not 
previously treated with AEDs. Patients are followed 
up for a minimum of 2 years. The primary outcome is 
time to 12- month remission from seizures. Secondary 
outcomes include time to treatment failure (including 
due to inadequate seizure control or unacceptable 
adverse reactions); time to first seizure; time to 24- month 
remission; adverse reactions and quality of life. All primary 
analyses will be on an intention to treat basis. Separate 
analyses will be undertaken for each arm. Health economic 
analysis will be conducted from the perspective of the NHS 
to assess the cost- effectiveness of each AED.
Ethics and dissemination This trial has been approved 
by the North West- Liverpool East REC (Ref. 12/NW/0361). 
The trial team will disseminate the results through 
scientific meetings, peer- reviewed publications and patient 
and public involvement.
Trial registration numbers EudraCT 2012-001884-64; 
ISRCTN30294119.
INTRODUCTION
Epilepsy is a common neurological condi-
tion and up to 3% of people will experience 
seizures at some time in their lives.1 Epilepsy 
is a complex condition with many different 
causes and seizures can take many different 
forms. It is uniquely stigmatising and has a 
negative impact on quality of life (QoL) and 
employment prospects.2 3 Antiepileptic drugs 
(AEDs) are the mainstay of treatment and may 
have to be taken for life. The ultimate goal of 
treatment is to maximise QoL by eliminating 
seizures at drug doses that do not cause side 
effects. However, for many patients, there is a 
Strengths and limitations of this study
 ► The study is adequately powered to examine the 
clinical effectiveness of standard and new antiepi-
leptic drugs (AEDs).
 ► The study is adequately powered to examine the 
cost- effectiveness of standard and AEDs.
 ► This is a long- term trial that will provide evidence of 
the long- term effects of some AEDs.
 ► A limitation is that the study is not blinded.
 ► A further limitation is the reliance on patient com-
pleted questionnaires, which should be offset by 
access to hospital episode statistic data.
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necessary trade- off between effective seizure control and 
side effects, which can diminish QoL.
Over the past 20 years, a number of new drugs have 
become available for the treatment of epilepsy. These 
new drugs have been approved for National Health 
Service (NHS) use on the basis of information from short- 
term trials. These trials do not provide information about 
the longer term outcomes, which inform decisions made 
by doctors and patients, nor do they provide any useful 
health economic data to inform policy.
The standard and new antiepileptic drugs (SANAD- I) 
trial began in 1999 and compared the effectiveness and 
cost- effectiveness of standard and new treatments that 
were available at that time.4 5 SANAD- I identified lamo-
trigine (a new drug) as an effective and cost- effective 
first- line treatment for patients with a focal epilepsy and 
confirmed that valproate (a standard treatment) should 
remain a first- line drug for patients with a generalised 
epilepsy or seizures that clinicians find difficult to clas-
sify. Since SANAD- I, a number of newer treatments have 
become available, the most promising of that are leve-
tiracetam and zonisamide. SANAD- II will include two 
randomised controlled trials (RCTs) run in parallel; 
arm A recruiting patients with focal epilepsy and arm B 
patients with generalised or unclassified epilepsy.
Rationale
Arm A
Arm A (focal epilepsy) of SANAD- II will compare lamo-
trigine, levetiracetam and zonisamide in patients with 
untreated focal onset seizures. While the focal epilep-
sies are further classified into a number of syndromes6 
largely according to aetiology and site of onset, it has 
been common practice to recruit a heterogeneous popu-
lation with focal onset seizures into epilepsy trials. There 
are currently no reliable data that indicate whether rela-
tive treatment responses differ among the focal epilep-
sies, indeed prognostic modelling of data from SANAD- I 
suggests that treatment effects are consistent across focal 
epilepsy syndromes as currently classified.4 7 In SANAD- II, 
we will recruit patients with focal onset seizures irrespec-
tive of syndrome, which will allow further opportunity 
to investigate treatment effects and factors, including 
syndrome, that influence those effects.
Lamotrigine was chosen as the ‘standard’ treatment 
as in SANAD- I, it was found to be superior to carbamaz-
epine for time to treatment failure and non- inferior to 
carbamazepine for time to 12- month remission, while 
the health economic analysis found lamotrigine a cost- 
effective alternative to carbamazepine.4
Levetiracetam is a commonly used AED with evidence 
for efficacy (non- inferiority (NI) to carbamazepine for 
6- month seizure remission) as monotherapy in focal 
epilepsy from regulatory studies with too short a dura-
tion of follow- up to inform policy.8 A second industry- 
sponsored unblinded trial compared levetiracetam with 
physicians’ choice of carbamazepine or valproate, but 
again follow- up was too short to inform treatment policy.9
Zonisamide is a drug that has been available for many 
years in Japan and other countries in South East Asia 
where it is commonly used both as initial monotherapy 
and as an add- on treatment and is licensed for use in the 
European Union and USA. Evidence for efficacy is from 
industry- sponsored regulatory studies demonstrating NI 
when compared with carbamazepine for 6- month seizure 
remission rates.10
Arm B
Arm B (generalised or unclassified epilepsy) of SANAD- II 
will compare levetiracetam and valproate in patients with 
generalised onset seizures or seizures that are difficult 
to classify. Generalised onset seizures represent a group 
of syndromes, most of which are currently classified as 
one of the idiopathic generalised epilepsies,6 which are 
largely classified according to seizure type and age of 
onset. While differing syndromes are recognised, there 
is currently no reliable evidence that relative treatment 
responses differ among syndromes, indeed prognostic 
modelling of data from SANAD- I indicates that relative 
treatment responses are consistent across syndromes. As 
in SANAD- I, patients enter Arm B of the trial based on 
a classification of seizures (generalised onset or difficult 
to classify), with patients further classified by syndrome 
where and when such a syndromic diagnosis can be made.
Few RCTs have been undertaken to assess the compar-
ative effects of AEDs in patients with generalised onset 
seizures or in those with seizures who are difficult to 
classify, even though these individuals represent over 
one- third of people with epilepsy. Valproate has for some 
time been recommended as a first- line treatment for such 
patients11 but without evidence from RCTs to support 
this recommendation. Cochrane reviews have compared 
valproate with other AEDs,12 13 but due to problems with 
power and epilepsy classification, none has shown an 
advantage for valproate. In arm B of SANAD- I,5 valproate 
was significantly more effective than lamotrigine and 
significantly better tolerated than topiramate. Also, a 
double- blind trial of 16 weeks therapy in childhood and 
juvenile absence epilepsy,14 valproate and ethosuximide 
were significantly superior to lamotrigine for the outcome 
treatment failure.
Valproate, however, remains a difficult drug for women 
of childbearing potential as it is associated with a higher 
rate of teratogenicity than alternatives (major malforma-
tion rate ~8%).15 There is also evidence that valproate can 
affect the intellectual development of children exposed in 
utero with up to one- third of children having a significant 
reduction in their IQ.16 In 2018, the European Medicines 
Agency (EMA) and Medicines and Healthcare products 
Regulatory Authority (MHRA) launched a pregnancy 
prevention programme for women taking valproate, and 
state that women of childbearing potential should not 
be prescribed valproate unless other treatments are inef-
fective or not tolerated.17 For women with generalised 
epilepsy, making a treatment choice is very challenging, 
with options including valproate, lamotrigine, which 
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is less effective but safer in pregnancy or levetiracetam 
for which the efficacy when compared with valproate is 
unknown and for which we have increasing evidence of 
relative safety in pregnancy.
TRIAL OUTCOMES
Primary outcome
The primary outcome of the trial is time to 12- month 
remission from seizures.
Secondary outcomes
The secondary outcomes are
1. Time to treatment failure.
2. Time to treatment failure due to inadequate seizure 
control. This event will have occurred when the clini-
cian and/or patient decides that treatment replace-
ment or withdrawal or the addition of a second AED 
is required due to the occurrence of a seizure on the 
maximum recommended dose of randomised drug or 
the maximum tolerated dose of the drug.
3. Time to treatment failure due to unacceptable adverse 
events. This event will have occurred when the patient 
experiences adverse events attributed to the drug ne-
cessitating its withdrawal.
4. Time to first seizure.
5. Time to 24- month remission.
6. Adverse reactions (ARs).
7. QoL.
8. Health economic outcomes expressed as the incremen-
tal cost per quality- adjusted life- year (QALY) gained.
TRIAL DESIGN
SANAD- II trial is a phase IV, multicentre, randomised, 
open- label controlled trial. Arm A of the trial recruits 
participants diagnosed with focal epilepsy and arm B—
with generalised or unclassified epilepsy. Trial partici-
pants are randomised to an AED within each arm. In arm 
A, the control treatment is lamotrigine and the new treat-
ments are levetiracetam and zonisamide, in treatment 
group ratio of 1:1:1. In arm B, the new treatment leveti-
racetam is compared with the control treatment valproate 
in treatment group ratio of 1:1. The sample size for the 
trial is 1510 participants (990 with focal epilepsy and 520 
with generalised or unclassified epilepsy).
Enrolment and randomisation
Screening and baseline
The SANAD- II trial will take place in NHS outpatient 
epilepsy, general neurology and paediatric (epilepsy and 
general) clinics in the UK (a full list of participating sites is 
available from the trial website). All patients meeting the 
eligibility criteria (table 1) will be invited to participate 
in the study and provided with an age and development- 
appropriate patient information sheet and consent form. 
Patients will be allowed sufficient time to discuss trial and 
to decide on their participation. Once consent has been 
obtained, the baseline data will be collected and patient 
will be progressed to randomisation.
Randomisation
The arm (A or B) to which the patient is assigned will 
be decided by the recruiting physician based on their 
epilepsy classification. Patients will then be randomised 
to one of the following treatments: to lamotrigine, leve-
tiracetam or zonisamide (in arm A) or to levetiracetam 
or valproate (in arm B). Randomisation will use a mini-
misation programme with a built- in random element 
using factors that will not be made known to individuals 
in charge of recruitment to minimise any potential for 
predicting allocation. Participants will be randomised 
using a secure (24 hours) web- based randomisation 
programme controlled centrally by the Clinical Trials 
Research Centre (CTRC). Randomised treatment should 
begin within 7 days of randomisation. The research 
team should ensure that the duration between obtaining 
consent, performing baseline assessments, randomisa-
tion and the start of trial treatment does not impact on 
the well- being of the participant.
Trial interventions
SANAD- II is a pragmatic trial that uses market authorised 
drugs within the terms of marketing authorisation. All 
treatments will be taken as formulations already licensed 
to be used in UK and there will be no modifications 
made to the products or their outer packaging. All treat-
ments will be prescribed as per routine NHS practice and 
dispensed by hospital and community pharmacies as they 
would normally be.
It is accepted that, for a variety of reasons including 
perceived or actual efficacy and tolerability, not all 
Table 1 Eligibility criteria
Inclusion 
criteria
a. Aged 5 years or older.
b. Two or more spontaneous seizures that 
require antiepileptic drug treatment.
c. Untreated and not previously treated 
with antiepileptic drugs, except emergency 
treatment in the past 2 weeks.
d. Antiepileptic drug monotherapy considered 
the most appropriate option.
e. Willing to provide consent (patients’ parent/
legal representative willing to give consent 
where the patient is aged under 16 years or is 
lacking capacity to consent).
Exclusion 
criteria
a. Provoked seizures only (eg, alcohol or drug 
induced).
b. Acute symptomatic seizures only (eg, within 
1 month from acute brain haemorrhage or 
brain injury or stroke).
c. Currently treated with antiepileptic drugs.
d. Progressive neurological disease (eg, known 
brain tumour).
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patients will take their medicines as prescribed. Patients 
will be asked about adherence in the QoL questionnaires, 
but no objective measurements of adherence are planned 
nor will the primary analyses be adjusted for actual or esti-
mated adherence.
SANAD- II is an unblinded trial therefore decisions 
about concomitant medications/treatments will depend 
on the local medical plan and clinical management.
All patients will be titrated to an initial maintenance 
dose, with dose adjustments made at subsequent appoint-
ments according to the clinical response and adverse 
effects. Guidelines for titration and initial maintenance 
dose are provided within the protocol (table 2), however, 
clinicians will be able to alter this to choose the titration 
rate and initial maintenance they think most appropriate 
for individual patients.
Table 2 Titration and initial maintenance dose
Arm A
Age >12 years
Lamotrigine Levetiracetam Zonisamide
25 mg once per day for 2 weeks 250 mg once per day for 2 weeks 50 mg once per day 2 weeks
25 mg two times per day for 2 weeks 250 mg two times per day for 2 weeks 50 mg two times per day for 2 weeks
50 mg two times per day for 2 weeks 250 mg morning and 500 mg night
for 2 weeks
50 mg am and 100 mg pm for 2 weeks
50 mg morning and 100 mg at 
night—initial target maintenance 
dose
500 mg two times per day—initial 
target maintenance dose
100 mg am 100 mg pm—initial target 
maintenance dose
Children aged 5–12 years
Lamotrigine Levetiracetam Zonisamide
0.5 mg/kg/ day as once a day dose 
for 2 weeks
10 mg/kg/day as two times daily 
regimen for 2 weeks
0.5–1 mg/kg/day as once or two times daily 
regimen (depending on the child's weight) for 2 
weeks
0.5 mg/kg/day as two times daily 
regimen for 2 weeks
20 mg/kg/day as two times daily 
regimen for 2 weeks
1–1.5 (maximum) mg/kg/day as two times daily 
regimen for 2 weeks
0.5 mg/kg am and 1.0 mg/kg pm for 
2 weeks
30 mg/kg/day as two times daily 
regimen for 2 weeks
2–2.5 (maximum) mg/kg/day as two times daily 
regimen for 2 weeks
1.0 mg/kg am and 1.0 mg/kg pm for 
2 weeks
40 mg/kg/day as two times daily 
regimen—initial target maintenance 
dose
3–4 mg/kg/day as two times daily regimen for 2 
weeks
1.5 mg/kg am and 1.5 mg/kg pm—
initial target maintenance dose
  5 mg/kg/day as two times daily regimen—initial 
target maintenance dose.
Arm B
Age >12 years
Valproate Levetiracetam
500 mg once per day for 2 weeks 250 mg once per day for 2 weeks
500 mg two times per day—initial 
target maintenance dose
250 mg two times per day for 2 weeks
  250 mg morning and 500 mg night for 2 weeks
  500 mg two times per day—initial target maintenance dose
Children aged 5–12 years
Valproate Levetiracetam
10 mg/kg/day as two times daily 
regimen for 2 weeks
10 mg/kg/day as two times daily regimen for 2 weeks
15 mg/kg/day as two times daily 
regimen for 2 weeks
20 mg/kg/day as twotimes daily regimen for 2 weeks
25 mg/kg/day as two times daily 
regimen—initial target maintenance 
dose
30 mg/kg/day as two times daily regimen for 2 weeks
  40 mg/kg/day as two times daily regimen—initial target maintenance dose
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The aim of treatment will be to control seizures with 
a minimum effective dose of drug. This will necessitate 
dosage modification (dose increased or reduced) if 
further seizures or adverse events occur as is usual clinical 
practice. Any changes in medication must be documented 
along with the justification for those changes. At the end 
of trial participation, the participants may continue their 
treatment as per local policy.
To avoid potentially confounding issues, ideally patients 
should not be recruited into other epilepsy trials.
Assessments and procedures
Schedule for follow-up
Patients were recruited over a 4.5- year period and 
follow- up will continue for further 2 years. The maximum 
time that a patient will receive their randomised treat-
ment is 6.5 years. Table 3 shows the schedule of follow- up.
All participants will be followed up whether they are still 
taking their allocated treatment or not. Where patients 
default from clinic follow- up, additional information will 
be sought from general practitioners who will be the main 
prescribers of AEDs in this trial. Patients will be followed 
up as per routine clinical practice and typically at 3, 6 and 
12 months and annually thereafter. Patients may be seen 
at other times as clinically indicated.
Where treatment is stopped, the participant will be 
asked to continue with the trial follow- up and to attend 
the follow- up visits.
Efficacy of the trial treatments will be measured 
throughout the trial using a number of measures. Data on 
seizures will provide a subjective measure of efficacy. QoL 
data obtained throughout the trial using age- appropriate 
Table 3 Schedule of follow- up
Procedures
Baseline 
(T0)*
Follow- up schedule
T0+3 
months
T0+6 
months
T0+12 months and 
annually thereafter
Signed consent form X       
Assessment of eligibility criteria X       
Contact details X       
Review of medical history including: X       
 ► Seizure history
 ► Neurological insult
 ► Febrile seizures
 ► Family history of epilepsy
 ► EEG results
 ► Imaging results (CT or MRI)
Further investigation (EEG/CT/MRI) (X)       
Allocation of study treatment X       
Issue of questionnaires in person or by post X X X X
Review of seizure occurrence and hospital admissions   X X X
Review of AED use (study treatment and concomitant):
 ►  Since last follow- up X X X
 ►  Changes made to treatment plan including reasons
Assessment of adverse reactions   (X) (X) (X)
Resource use   X X X
Reissue of questionnaire by post or at site to non- responders typically 
3 weeks later
(X) (X) (X) (X)
Telephone follow- up of questionnaire non- responders typically 3 weeks 
later
(X) (X) (X) (X)
Special assay or procedure consent and 
obtain saliva or blood sample for later DNA 
analysis
Consent and obtain saliva 
or blood sample for later 
DNA analysis
(X)       
(X)—as indicated/appropriate.
EEG = Electroencephalogram
*At baseline, all procedures should be done before study intervention.
AED, antiepileptic drug.
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questionnaire booklets (table 4) can be used as a subjec-
tive measure of efficacy.
Assessment of ARs will be undertaken at each study visit.
QOL and utility assessments
For adults, QOL outcomes will be assessed using subscales 
of the Quality of Life in Newly Diagnosed Epilespy 
(NEWQOL) battery and the Impact of Epilepsy Scale.18 
For children and adolescents aged <16 years, QoL assess-
ment will involve both patient and parent- based measures: 
children aged 8–15 years will complete a generic health 
status measure validated for use in epilepsy, the KINDL19; 
and the ‘epilepsy impact’ and ‘attitude to epilepsy’ 
subscales of the Quality of Life in Epilepsy for Adults 
(QOLIE- AD).20 Parents of all children will also complete 
proxy QoL questionnaires.
Utility scores will be elicited directly from trial partic-
ipants (or indirectly via parents/guardians). Adult 
and adolescent patients will be asked to complete the 
EQ- 5D- 3L questionnaire and Visual Analogue Scale. The 
EQ- 5D- 3L has been used previously in children, but it 
has not been formally validated,21 and EQ- 5D- 3L weights 
are validated for adults aged ≥18 years. The currently 
recommended approach of using parental proxy reports 
of QoL for this age group will be used.22 EQ- 5D- 3L- Y 
(youth version) will additionally be administered to chil-
dren aged 8–15 years. All trial participants will be asked 
to complete an epilepsy- specific utility measure, based on 
the NEWQOL- 6D questionnaire.23
Patients and/or parents/guardians will be completing 
questionnaires at baseline and at specific time points 
throughout the trial.
Resources use and cost data
Direct costs of healthcare resources used by patients in 
the trial will be collected in three ways:
1. A modified version of the Client Service Receipt 
Inventory24 to assess patients’ use of primary and com-
munity care services and personal social services (eg, 
primary care services (NHS Direct, walk- in treatment 
centres, home visits, etc).
2. Patients’ use of secondary care services as Hospital 
Episode Statistics (HES) data. Downloaded Health-
care Resource Group data will include information on 
outpatient epilepsy, general neurology and paediatric 
clinics visits; accident and emergency attendance and 
length (and nature) of hospitalisations.
3. Resources triggered by ARs will be captured in the 
follow- up case report form (CRF) for each patient 
experiencing a serious AR requiring hospitalisation. 
Because of potential issues related to completeness of 
routine data, these will be used to compliment HES 
data.
4. Unit costs will be taken from the NHS reference costs 
database25 and other appropriate sources.26 27
Genetic substudy
DNA collection will be included as an option in SANAD- II 
in order that refusal will not preclude from trial partic-
ipation. Whole blood or saliva samples will be shipped 
to a central laboratory at The University of Liverpool for 
extraction and storage. No genotyping of DNA samples 
will be undertaken as part of SANAD- II. Samples will 
instead be genotyped in future projects and data arising 
from that analysis included in international epilepsy 
genomics initiatives. Identification of genetic factors asso-
ciated with response to treatment in epilepsy is important 
and may ultimately help to optimise efficacy, tolerability 
and safety of AEDs.
Sample size calculation
SANAD- II is powered to detect NI of the new AEDs (leve-
tiracetam and zonisamide) compared with standard 
treatments (lamotrigine or valproate) for the primary 
outcome time to 12- month remission. A new drug might 
become a standard first- line treatment if it is proven to 
be non- inferior for efficacy but superior for tolerability 
when compared with a standard treatment—tolerability is 
examined in secondary outcomes including time to treat-
ment failure for adverse effects. Powering the study for 
NI will also provide sufficient power to detect important 
differences between treatment policies.
The International League Against Epilepsy (ILAE) 
Commission on Antiepileptic Drugs defined limits of 
equivalence of ±10% for the primary outcome in AED 
monotherapy studies.28 However, the commission was not 
explicit as to whether this should be on the HR or abso-
lute scale. No empirical work has yet been undertaken 
Table 4 Age- appropriate questionnaire booklets
Participant age Questionnaire booklet completed by Questionnaire booklet content
5–7 Participant N/A
Parent/carer Kiddy- KINDL, EQ- 5D- 3L & EQ- VAS, NEWQOL- 6D
8–11 (children) Participant Kid- KINDL, EQ- 5D- 3L- Y & EQ- VAS, QOLIE- AD
Parent/carer Kid- KINDL, EQ- 5D- 3L & EQ- VAS, NEWQOL- 6D
12–15 (young people) Participant Kiddo- KINDL, EQ- 5D- 3L- Y & EQ- VAS, QOLIE- AD
Parent/carer Kiddo- KINDL, EQ- 5D- 3L & EQ- VAS, NEWQOL- 6D
≥16 (adult) Participant Impact of Epilepsy Scale, EQ- 5D- 3L & EQ- VAS, NEWQOL- 6D
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to underpin the choice of equivalence or NI margins in 
epilepsy trials. The chief investigator has given numerous 
seminars and lectures in the UK and elsewhere about 
epilepsy trial methodology and the audience typically vote 
for a margin of 10% around absolute differences between 
AEDs for monotherapy studies when given examples of 
margins ranging from 20% to 5%.
Calculations have been informed by the SANAD- I 
study, which estimated the 12- month remission- free 
probability (at 24 months) as 0.43 (exponential hazard 
rate of 0.0352) for lamotrigine (arm A standard) and 
0.31 (exponential hazard rate of 0.0488) for valproate 
(arm B standard). The calculations assume a HR of 1.0, 
80% power, and allowance for approximately 5% losses 
to follow- up throughout, as occurred in SANAD- I. For 
patients with focal- onset seizures (arm A), two primary 
comparisons are of interest (levetiracetam vs lamotrigine 
and zonisamide vs lamotrigine), therefore, the one- 
sided significance level has been divided by two (one- 
side alpha 0.0125). Assuming a 10% absolute difference 
in survival probability, the NI margin on the HR scale is 
ln(0.43)/ln(0.53)=1.329. After adjusting for 5% losses 
to follow- up, 330 patients are required in each of three 
treatment groups (990 total for arm A). For patients with 
generalised- onset seizures or seizures that are difficult to 
classify (arm B), there is only one comparison of interest 
(levetiracetam vs valproate). Assuming a 10% absolute 
difference in survival probability, the NI margin on the 
HR scale is ln(0.31)/ln(0.41)=1.314 for arm B. Therefore, 
with a one- sided alpha of 0.025, 260 patients are required 
in each of two treatment groups allowing for 5% losses 
to follow- up (520 total for arm B). The total number of 
patients required is 1510.
Statistical analysis
All primary analyses will be on an intention to treat (ITT) 
basis including all randomised patients retained in their 
randomised treatment groups. Separate analyses will be 
undertaken for each randomisation arm. The interval (in 
days) from randomisation to occurrence of a 12- month 
remission will be summarised by Kaplan- Meier curves for 
each treatment group. Survival regression models will be 
explored; two different models will be used: (1) including 
the treatment effect only using treatment indicator vari-
ables and (2) including the treatment effect together 
with covariates. The impact of centre effect on the treat-
ment comparison will be investigated using both fixed 
and random effect models. A per protocol analysis will be 
undertaken to assess the robustness of ITT analyses. For 
arm B trial, an additional analysis of the primary outcome 
will add a stratification variable to the model: seizure type 
(generalised/unclassified).
A similar analysis strategy will be employed for the 
other secondary time to event outcomes. For time to 
treatment failure, further analysis will be undertaken to 
assess the two main reasons for treatment failure—inad-
equate seizure control and unacceptable adverse effects. 
To allow for possible dependence between the different 
withdrawal risks, cumulative incidence analyses will be 
presented.29
The Haybittle- Peto approach will be employed for 
each interim analysis, with 99.9% CIs calculated for 
interim analysis effect estimates. The final analysis will 
be undertaken at the end of the trial when all patients 
have a minimum 2- year follow- up data (6.5 years after 
the first patient is randomised) and 95% CIs will be 
calculated.
QoL data will be analysed longitudinally to explore 
between treatment changes in scale scores over time, 
taking account of baseline QoL.
For the analysis of ARs, all patients who received 
any amount of each study drug will be included in the 
safety analysis dataset in the treatment group they actu-
ally received. All ARs and serious ARs reported by the 
clinical investigators will be presented, identified by 
treatment group. ARs will be grouped according to a 
prespecified coding system and tabulated. The number 
(and percentage) of patients experiencing each AR, and 
the number (and percentage) of occurrences of each 
AR will be presented. No formal statistical testing will be 
undertaken.
Health economic evaluation
For the health economic analyses, the perspective of 
the NHS and Personal Social Services will be adopted 
for costing purposes. It will be assessed whether leveti-
racetam or zonisamide as monotherapy in newly treated 
focal epilepsy is cost- effective by estimating the incre-
mental cost- utility and cost- effectiveness ratios relative 
to lamotrigine and to each other. The same approach 
will be used to compare levetiracetam and valproate for 
generalised- onset seizures. A cost consequence analysis30 
will be conducted to consider non- health benefits that 
are neither captured within the QALY calculation, nor 
in the cost- effectiveness analyses. Potential non- health 
benefits that will be measured include social activity, 
time in work or school and patients’ driving (captured 
in the NEWQOL battery). Additional non- health benefits 
(perceived stigma, control and cognitive effects) will also 
be captured in the NEWQOL- 6D.23
Sensitivity analyses will be conducted to test the robust-
ness of our findings. These analyses will be based on 
the observed distributions of outcome and costs to test 
whether, and to what extent, the incremental cost- utility 
and cost- effectiveness ratios are sensitive to key assump-
tions in the analysis. Uncertainty in parameter estimates 
will be addressed through the application of bootstrap-
ping and the estimation of cost- effectiveness acceptability 
curves.
The estimated incremental cost per QALY will be 
compared with the threshold for cost- effectiveness oper-
ating in the UK, and the incremental cost per seizure 
will be avoided and per 12- month remission will be 
compared with the results of other economic assessments 
of AEDs.31 32
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Ethics and dissemination
Ethics
The trial protocol complies with the Standard Protocol 
Items: Recommendations for Interventional Trials 
reporting guidelines.33 All relevant trial documentations 
have been approved by the North West—Liverpool East 
Research Ethics Committee (Ref: 12/NW/0361). This 
trial falls within the remit of the EU Directive 2001/20/
EC,34 transposed into UK law as the UK Statutory Instru-
ment 2004 No 1031: Medicines for Human Use (Clin-
ical Trials) Regulations 2004 as amended.35 SANAD- II 
has been registered with the MHRA and was granted 
a Clinical Trial Authorisation for Notification prior to 
initiation.
Dissemination
The trial team plans to disseminate the SANAD- II results 
by presentations at national (eg, Association of British 
Neurologists (ABN) and international (eg, ILAE—Euro-
pean congress, or ILAE international Epilepsy Congress) 
meetings as well as publications in leading peer- reviewed 
journals and through patient and public involvement. 
Authorship of any documents will follow International 
Committeee of Medical Journal Editors (ICMJE) Recom-
mendations 2018.
Data collection and trial monitoring
Data collection
Data management for SANAD- II is performed by the 
CTRC at University of Liverpool. Participating centres 
will be expected to each maintain a file of essential trial 
documentation (Site File), which will be provided by the 
coordinating centre and keep copies of all completed 
CRFs. Data collection will use paper CRFs and participant 
completed questionnaires.
Trial monitoring
Trial Oversight Committees have been formed in relation 
to the monitoring. This includes an Independent Data 
and Safety Monitoring Committee (IDSMC), consisting 
of independent epilepsy experts and statisticians; A Trial 
Management Group (TMG) consisting of the chief inves-
tigator, trial manager, trial statisticians, sponsor repre-
sentatives, several principal investigators and a Trial 
Steering Committee (TSC) consisting of two indepen-
dent epilepsy clinicians, an independent statistician and 
a lay representative, in addition to select members of the 
TMG.
Trial monitoring is informed by a risk assessment to 
determine the level and type of monitoring required 
for specific hazards. The IDSMC will monitor partic-
ipant safety including any unexpected ARs. ARs will be 
reported to the MHRA and to the Liverpool East Research 
Ethics Committee via annual Data and Safety Monitoring 
Reports. The committees will also monitor recruitment 
rates and adherence to Good Clinical Practice (GCP) 
guidance.
Patient and public involvement
SANAD- II was designed in collaboration with epilepsy 
action and has a patient and public involvement repre-
sentative in the TSC.
Time frame and trial status
The study opened to recruitment in 2013 and completed 
recruitment in June 2017. Participants are followed up 
for a minimum of 2 years and a maximum of 6.5 years. 
Follow- up visits and data collection will continue until 
June 2019.
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